1. Home
  2. SPRO vs NVX Comparison

SPRO vs NVX Comparison

Compare SPRO & NVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Spero Therapeutics Inc.

SPRO

Spero Therapeutics Inc.

HOLD

Current Price

$2.24

Market Cap

124.5M

Sector

Health Care

ML Signal

HOLD

Logo NOVONIX Limited American Depository Shares

NVX

NOVONIX Limited American Depository Shares

HOLD

Current Price

$0.66

Market Cap

146.4M

Sector

Miscellaneous

ML Signal

HOLD

Company Overview

Basic Information
Metric
SPRO
NVX
Founded
2013
2012
Country
United States
Australia
Employees
N/A
192
Industry
Biotechnology: Pharmaceutical Preparations
Industrial Machinery/Components
Sector
Health Care
Miscellaneous
Exchange
Nasdaq
Nasdaq
Market Cap
124.5M
146.4M
IPO Year
2017
N/A

Fundamental Metrics

Financial Performance
Metric
SPRO
NVX
Price
$2.24
$0.66
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
261.3K
404.4K
Earning Date
03-26-2026
04-23-2026
Dividend Yield
N/A
N/A
EPS Growth
111.81
N/A
EPS
0.15
N/A
Revenue
$66,802,000.00
N/A
Revenue This Year
N/A
$3,904.19
Revenue Next Year
N/A
$91.72
P/E Ratio
$15.53
N/A
Revenue Growth
39.24
N/A
52 Week Low
$0.51
$0.63
52 Week High
$3.09
$3.86

Technical Indicators

Market Signals
Indicator
SPRO
NVX
Relative Strength Index (RSI) 39.83 35.65
Support Level $2.15 $0.63
Resistance Level $2.44 $1.02
Average True Range (ATR) 0.13 0.05
MACD -0.02 -0.00
Stochastic Oscillator 4.35 8.22

Price Performance

Historical Comparison
SPRO
NVX

About SPRO Spero Therapeutics Inc.

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

About NVX NOVONIX Limited American Depository Shares

NOVONIX Ltd is a battery technology company developing and scaling materials and equipment critical to the lithium-ion battery supply chain. The company has three operating segments: Battery Materials: It develops and manufactures battery anode materials, ii) Battery Technology: It develops and manufactures battery cell testing equipment, performs consulting services and carries out research and development in battery development, and Graphite Exploration: It manages the maintenance and future development of Mount Dromedary natural graphite deposit. The majority of the company's revenue is derived from the Battery Technology segment. Geographically, the maximum revenue is derived from North America, followed by Asia, and Europe.

Share on Social Networks: